Circio Holding and NeoRegen Biotech have signed a second Material Transfer Agreement (MTA) to advance their ongoing collaboration for the delivery of circular RNA (circRNA) expression-based therapeutics.   The collaboration now is progressing to the in vivo preclinical stage following successful proof-of-concept (POC) results from in vitro studies.  The collaboration was formed in 2023 with […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!